Immunotherapy before surgery for advanced rectal cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a treatment plan for locally advanced rectal cancer that combines chemotherapy and radiation with an immunotherapy drug (PD-1 inhibitor) before surgery. The goal is to shrink the tumor and improve the chance of successful surgery and long-term control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with rectal adenocarcinoma (a type of rectal cancer).
- The tumor is in the middle or lower part of the rectum, within 12 cm from the anal verge, and is locally advanced (stage T3 or T4, no distant spread).
- You have not had any prior treatment for cancer (such as chemo, radiation, or immunotherapy).
- Your cancer is MSS (microsatellite stable) type, as shown by a PCR test.
- You are between 18 and 75 years old and are generally healthy (ECOG 0-1).
- Your blood counts and liver/kidney function are within normal limits, and you do not have serious medical conditions or a history of autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy and an immunotherapy drug (a PD-1 inhibitor) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can improve outcomes compared to standard treatment.
This trial tests a combination of a cancer-killing virus (oncolytic virotherapy) and an immunotherapy drug (pembrolizumab) given before surgery for a certain type of rectal cancer. It aims to see if this approach helps shrink the tumor and improve outcomes for patients whose tumors have a normal DNA repair system (pMMR).
This trial tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemoradiation and targeted therapy improves outcomes for locally advanced rectal cancer. It is for patients who have not had prior treatment and do not have certain genetic markers (BRAF mutation or MSI-H).
This study tests a combination of chemotherapy, radiation, and an immunotherapy drug (called anti-PD-1) before surgery for rectal cancer that has not spread. The goal is to see if this approach can shrink or eliminate the tumor, potentially improving outcomes.
This trial studies giving long-course radiation and chemotherapy before surgery, plus an immunotherapy medicine (PD-1) to help the tumor shrink more. It’s for people with stage II or III rectal cancer that has not spread to distant organs.
This trial tests whether giving chemotherapy and an immunotherapy drug before surgery can help shrink rectal cancer tumors and improve outcomes. It is for patients whose tumors are not caused by a specific genetic mismatch repair problem.
Hear when a new Rectal Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.